What is HC Wainwright’s Forecast for APTO FY2024 Earnings?

Posted by ABMN Staff on Nov 27th, 2024

Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Aptose Biosciences in a report issued on Wednesday, November 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($1.79) per share for the year. HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.35) EPS.

Separately, StockNews.com started coverage on Aptose Biosciences in a research note on Thursday, November 21st. They issued a “hold” rating on the stock.

Read Our Latest Analysis on APTO

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.18 on Monday. The business’s 50-day moving average price is $0.37 and its two-hundred day moving average price is $0.58. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.91. The company has a market capitalization of $3.22 million, a P/E ratio of -0.06 and a beta of 1.26.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the SEC. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.